TRAIP suppresses bladder cancer progression by catalyzing K48-linked polyubiquitination of MYC

Oncogene. 2024 Feb;43(7):470-483. doi: 10.1038/s41388-023-02922-0. Epub 2023 Dec 20.

Abstract

TRAF-interacting protein (TRAIP), an E3 ligase containing a RING domain, has emerged as a significant contributor to maintaining genome integrity and is closely associated with cancer. Our study reveals that TRAIP shows reduced expression in bladder cancer (BLCA), which correlates with an unfavorable prognosis. In vitro and in vivo, TRAIP inhibits proliferation and migration of BLCA cells. MYC has been identified as a novel target for TRAIP, wherein direct interaction promotes K48-linked polyubiquitination at neighboring K428 and K430 residues, ultimately resulting in proteasome-dependent degradation and downregulation of MYC transcriptional activity. This mechanism effectively impedes the progression of BLCA. Restoring MYC expression reverses suppressed proliferation and migration of BLCA cells induced by TRAIP. Moreover, our results suggest that MYC may bind to the transcriptional start region of TRAIP, thereby exerting regulatory control over TRAIP transcription. Consequently, this interaction establishes a negative feedback loop that regulates MYC expression, preventing excessive levels. Taken together, this study reveals a mechanism that TRAIP inhibits proliferation and migration of BLCA by promoting ubiquitin-mediated degradation of MYC.

MeSH terms

  • Humans
  • Tumor Necrosis Factor Receptor-Associated Peptides and Proteins* / genetics
  • Tumor Necrosis Factor Receptor-Associated Peptides and Proteins* / metabolism
  • Ubiquitin-Protein Ligases / genetics
  • Ubiquitin-Protein Ligases / metabolism
  • Ubiquitination
  • Urinary Bladder Neoplasms* / genetics

Substances

  • Tumor Necrosis Factor Receptor-Associated Peptides and Proteins
  • Ubiquitin-Protein Ligases
  • TRAIP protein, human